Versant Venture Management, LLC

CIK 0001560009 · SAN FRANCISCO, CA · Quarter end: 2026-06-30 · Filed on: 2026-08-12 · Open the SEC source ↗

Versant Venture Management, LLC reported 8 positions worth $162.6M as of June 30, 2026 (13F filed August 12, 2026). Largest holding: GLUE (47.3%).

Portfolio Value (AUM)Total value of the fund's US stock portfolio reported to the SEC.

$162.6M

2026 Q2

Positions

Top-10 ConcentrationHow much of the portfolio sits in the 10 largest holdings. High = concentrated bets.

100.0%

Est. Net Flow (Q)

—

2026 Q2

Positions Changes Mix History BacktestPRO

8 positions shown

#	Symbol	Company	Type	Value ↓	% Port.	Shares	1Y	YTD
▸ 1	GLUE	Monte Rosa Therapeutics, Inc.	SH	$77.0M	47.34%	3,180,780	—	—
▸ 2	IPSC	Century Therapeutics, Inc.	SH	$29.8M	18.33%	12,166,109	—	—
▸ 3	JBIO	Jade Biosciences, Inc.	SH	$22.0M	13.55%	991,783	—	—
▸ 4	LENZ	Lenz Therapeutics, Inc.	SH	$15.1M	9.28%	2,656,888	—	—
▸ 5	CTNM	Contineum Therapeutics, Inc.	SH	$8.9M	5.47%	542,628	—	—
▸ 6	CRSP	CRISPR Therapeutics AG	SH	$8.1M	4.99%	148,831	—	—
▸ 7	83086J200	Skye Bioscience, Inc.	SH	$1.4M	0.86%	2,007,704	—	—
▸ 8	OVASUSD	Tempest Therapeutics, Inc.	SH	$299.4K	0.18%	269,772	—	—

Read the 2026-Q2 quarterly report · 13F Filing Calendar

Frequently Asked Questions

What stocks does Versant Venture Management, LLC hold as of Q2 2026?

Versant Venture Management, LLC reported 8 positions worth $162.6M in its Q2 2026 13F filing. Largest positions: GLUE (47.3%), IPSC (18.3%), JBIO (13.6%), LENZ (9.3%) and CTNM (5.5%).

What did Versant Venture Management, LLC buy in Q2 2026?

No previous quarter is available yet; the comparison appears with the next filing.

What did Versant Venture Management, LLC sell in Q2 2026?

No previous quarter is available yet.

13F data shows quarter-end positions, is delayed by up to 45 days and covers only long positions in US-listed securities; short positions, most derivatives and non-US assets are not reported.